HRSA published in the Federal Register a proposed rule that, if published as final, will rescind the insulin/injectable epinephrine final rule impacting FQHCs participating in the 340B Program. There is a 30-day public comment period. NACHC is working on a comment template and encourages health centers to weigh in on this proposal by submitting comments supporting the premise that the existing Trump Administration final rule would not increase access for patients but would place an immense burden on the health center program. If you have any questions, please contact regulatoryaffairs@nachc.org.
